Benzinga | Jun 17, 2021 09:21AM EDT

B of A Securities Downgrades CureVac to Neutral, Announces $50 Price Target

B of A Securities analyst Geoff Meacham downgrades CureVac (NASDAQ:CVAC) from Buy to Neutral and announces $50 price target.B of A Securities analyst Geoff Meacham downgrades CureVac (NASDAQ:CVAC) from Buy to Neutral and announces $50 price target.